The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Personally not particularly worried by there being, as yet, no US partner.bearing in mind it took over a year to agree the cooper tie up from the c/e mark award, im not sure we should be too worried yet. as it has only been a few weeks since FDA approval.whilst im sure fum have been in some form of discussions with possible us partners for some time (they have said as much in formal announcements) i'm personally not sure that they would have wanted to reach contingent agreements based on condition of getting FDA approval. if i were seeking to conduct negotiations i would wish to have the strongest possible negotiating weapons in my armoury,i.e. formal fda approval,before taking the discussions to a serious and advanced level. it seems to me it's the difference between saying 'well now chaps,if we get FDA approval what would you be willing to do?"and "ok chaps,we have formal fda approval for our product,what terms are you prepared to offer to secure our involvement?".
the differing views expressed by other today are perfectly reasonable and tenable and im certainly no expert in such matters,but for the moment i'm very comfortable with the progress so far.all just my opinion of course.
Some thoughts on SP stagnation.
When speculation morphs into reality, totally different indicators come into play. Tangible components appear, and to an extant, exact science can be applied to the existing parameters.
Many investors have become 'investor savvy' and no longer believe in future pie-in-sky valuations, mostly projected by (shifty) house brokers.
Frequently banded terms like 'tree shake going on', 'seller on the scene' 'price held back' on BB's are used to justify lack of expected SP progress. There will be SP movement when milestones are reached, however, there will only be one factor that will significantly drive the SP higher and keep it there.
The significant factor that matters is whether a large investment institution shows confidence in investing in Eroxon. They do their own due diligence and will only invest when they feel there is going to be a return on their investment. Lack of this is the only thing keeping the SP where it is, in my opinion.
LBO is pragmatic and would not invest on 'gut feelings', however it is a high risk averse institution, To date their involvement alone has underpinned the SP.
Why are Pharmaceuticals not making a play for FUM. Well, perhaps, due to the simplicity of the Eroxon gel formulation, they may be using R&D teams to try and to create their own formulation, outside the parameters of the existing patent.
Also, maybe the BoD are shy of multi tasking.
By now everyone who needs to know about FUM should know about the company and it's product.
Whether FUM is premier league or league one, it's going to make money.
I think it was very high then based on optimistic speculation but also assuming that it would take off if they could get it approved. Its approved now and and there isn't this mad rush from big pharma to purchase so speculators are cooling off. That said it does seem mad that it reached pound then and only 60p now. Thats AIM for ya.
My thoughts exactly - I got really anxious when I saw that no announcement of a licensing deal coming through after the FDA approval. If the product or board are worth anything they would have the deal lined up based on FDA approval .
For that reason I sold out a couple of weeks ago as who knows what way sales will go but my confidence is a bit shaken when no deal could be sealed (not sure if this is the fault of the product or the board). That said I sold at 50p and it is just coming back from 60 so I'm not pretending to know everything but its not exactly a sure fire bet now given that on the absence of a US deal the value of FUM will be completely based on how well the EU/UK sales go and I don't know if the people in charge of this have the ability to push it forward - perhaps they have.
Well that sp fell off the cliff at the end today, something you said?? Lol
Brugge95 - the shareprice for FUM is quite an enigma.
Amazingly in years past the sp was higher than now when no trials had been completed - all on the promise that it would work. I can think back to 10 years ago paying the same price for the shares as now. I wonder if because of the nature of the principal product being one for a basic human use (we have yet to make any progress in the topical painkiller or cannabis compounds markets). Is the product too unsavoury, too seedy a background for many investors ?
Most new and upcoming businesses, see their sp making great strides early on, simply on imagined prospects whereas I've long felt that it is only on actual sales and profit figures that we will really see FUM's sp move. It's been a long game slowly unfolding with FUM, some will say it will happen once news of the US participant is announced but that's only one more step forward.
Once those financial figures are out and we can clearly see for ourselves it's not another emperor wearing new clothes (sorry to Hans Christian Andersen for bringing sex into your splendid parable) - then I'm quite sure the sp will rise and quickly go beyond £1 and this should become a true cash cow of a share. Until then, patience is the name of the game here - it will be rewarded I am quite sure. GLA
I suspect it’s because there is still no licensing/sales deal In place. Without it, there is no value and not many are willing to take the risk and jump in (To be honest I really don’t understand why no agreement was already in place, even if it was based on the understanding of no approval, no deal, although we still don’t know how close they are to signing one). That said, once a license/sales agreement is in place, I would suspect lift off. Just my two pennyworth for what it’s worth.
I have always invested in stocks that I had a gut feeling for.
I have in the most part done well overall.
I saw Fum and knew this was a share for me.The wait for the permission to sell into America was
a worry as There was always the possibility that the permission would not be granted in any event this turned into a damp squid?
I am not very knowledgeable and I thought Ameriica was the game changer? And the SP would shoot up?
We are all aware that the SP has stayed around 60p and seems to be stuck?
Please can somebody explain what is going on?
America was the biggest m market ?
Is FUM expecting. A takeover bid?
How will the SP increase in the.short term?
Very low volume today coincides with 4th July holiday
Look forward to fuzz's post on it then :)
If you bother to look in the comments section it gives the time stamps of all parts of the discussion, I think the poster is saying people should mention FUM as other viewers could be potential customers if they don’t know about the product
The video is 3 hours long. Mind pointing us to the time stamp of the quote for ease of reference
Https://www.youtube.com/watch?v=GNCpG1fkMBA
You lot should comment on this podcast about FUM.
Patience everyone, patience. The knockers are becoming desperate, they’ve downplayed Eroxon on both Boots and Amazons sites, more good news in the pipeline to come and I would suggest lots.
This train has started to roll and there ain’t going to be no stopping, this is reflected in their desperate posts and actions becoming more and more irrational by the day. Personally I wouldn’t be holding my breathe for the American deal, Futura are going to want a great deal, they must all by now be knocking on FUM’s door looking to be the chosen one.
Patent extension, good data from GB and Europe and this is off too the moon.
Or is it just that the wine makes the wife look much more attractive....burp, hic.....zzzzzzz LOL
@Kdonkey was this the culprit? But look on the bright side!
https://www.dailymail.co.uk/health/article-12243509/Study-sex-shows-happens-bedroom-drink-red-wine.html
Why is the article referencing old studies/articles relating to med 2005?
That 77 is the number of reviews since sales began on Amazon well over a month ago i.e. probably under 1% of buyers bother writing reviews.
1.28%
That link mentions the Amazon review score is from 77 reviews. It doesn't mention that there have been over 6000 sales on Amazon in the last month. The 77 is a tiny proportion, the 6000 number tells us a lot more.
Fair enough Kdonkey.i don't have a strong view either way.just felt that if there has been persistent selling down by LO at any significant level we might have expected an RNS by now.im not particularly bothered if they have been selling down as there could be any number of reasons for that,some not necessarily directly related to their view on fum"s prospects. anyway time as usual will probably tell. hope the hangover is improving! imo
Italain, I disagree with you, as I think there is/has been a seller.
Most PI don't buy/sell round figures of shares. They buy in round up monetary terms, say 1000 quid, so will get how many shares including costs. If you look at at past trading there has been a lot of units of 1000 shares being sold at a time. You'll also see that the more shares are being traded the more of these rounded up shares are sold.
Personally I don't think they are PI's. But that is my opinion. If you look before Lom got the 10 mil shares, they did actually let the market know they had reduced their holdings (and there was a lot of 1000 units sold prior to that). I will admit that Lom then had to redo the RNS because they' just got 10 mil shares. But that doesn't negate the effect they had reduced their holdings.
Hope that makes sense, as struggling with a severe hangover....d'oh.
but as I said imo
That is my point.i'm not sure there is any "background seller"
Peeps buy and sell, fact. 'Background sellers'lol